Cantor Fitzgerald Reaffirms Overweight Rating on Precigen (PGEN)

Precigen, Inc. (NASDAQ:PGEN) is one of the must-buy penny stocks to invest in. On August 19, Cantor Fitzgerald reaffirmed its “Overweight” rating on Precigen stock. The firm expressed growing confidence in Precigen’s upcoming launch of Papzimeos, the company’s newly approved product, following recent discussions with the company. Papzimeos received full FDA approval as the first and only therapy for adults with recurrent respiratory papillomatosis (RRP), marking a major milestone for Precigen. Precigen set the wholesale acquisition cost for a full treatment cycle of the drug at $460,000.

The analysts’ thesis highlights Papzimeos as a significant revenue opportunity due to its unique position as the only FDA-approved RRP treatment and the company’s strategic preparations for its commercial launch. As such, Cantor Fitzgerald updated its financial model, estimating Precigen’s equity value at approximately $1.7-1.8 billion, which is about 3.3 times the projected peak sales for the company’s products, based on a discounted cash flow analysis.

Precigen, Inc. (NASDAQ:PGEN) is a biotech firm focused on gene and cell therapies for cancer, autoimmune conditions, and rare diseases. Using synthetic biology, its pipeline features innovative platforms—UltraCAR-T, ActoBiotics, and AdenoVerse—aimed at delivering precise, long-lasting, and cost-effective treatments.

While we acknowledge the potential of PGEN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 6 Best Railroad Stocks to Buy Right Now and 11 Best Very Cheap Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.